HeartSciences (HSCS) EBT Margin (2021 - 2025)

HeartSciences' (HSCS) quarterly EBT Margin came in at 97269.0% in Q4 2025, up 89.34% on a QoQ basis from 912409.63% in Q3 2025.

HeartSciences (HSCS) EBT Margin (2021 - 2025) Analysis & Trends

HeartSciences (HSCS) has 5 years of EBT Margin data on file, last reported at 97269.0% in Q4 2025.

Quarterly EBT Margin changed N/A year-over-year to 97269.0% in Q4 2025, while the trailing twelve-month figure through Apr 2026 was 283247.04% (down 1659773.0% YoY) and the FY2026 annual result came in at 596553.65%, down 5900732.0% from the prior year.
EBT Margin improved to 97269.0% in Q4 2025, from 912409.63% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 10048.78% in Q3 2021 to a low of 912409.63% in Q3 2025.
A 5-year average of 262579.64% and a median of 97280.54% in 2024 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2023 — EBT Margin plunged 59235836 bps — and 2024, when it surged 54029817 bps.
Tracing HSCS's EBT Margin over 5 years: stood at 10048.78% in 2021, then plunged by 3586 bps to 370391.66% in 2022, then grew by 3 bps to 357732.28% in 2023, then jumped by 73 bps to 97292.09% in 2024, then advanced by 0 bps to 97269.0% in 2025.
The last three EBT Margin figures came in at 97269.0% (Q4 2025), 912409.63% (Q3 2025), and 48304.62% (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	12.10%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	23.74%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	18.70%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	29.86%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	8.91%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	18.32%
10	HeartSciences	6.54 Mn	4.84 Mn	-	-

Download Data